Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting

Chimeric antigen receptor anti-CD19 (CAR19)-T cell immunotherapy-induced clinical remissions in CD19(+) B cell lymphomas are often short lived. We tested whether CAR19-engineering of the CD1d-restricted invariant natural killer T (iNKT) cells would result in enhanced anti-lymphoma activity. CAR19-iN...

Descripción completa

Detalles Bibliográficos
Autores principales: Rotolo, Antonia, Caputo, Valentina S., Holubova, Monika, Baxan, Nicoleta, Dubois, Olivier, Chaudhry, Mohammed Suhail, Xiao, Xiaolin, Goudevenou, Katerina, Pitcher, David S., Petevi, Kyriaki, Kachramanoglou, Carolina, Iles, Sandra, Naresh, Kikkeri, Maher, John, Karadimitris, Anastasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179961/
https://www.ncbi.nlm.nih.gov/pubmed/30300581
http://dx.doi.org/10.1016/j.ccell.2018.08.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179961/
https://www.ncbi.nlm.nih.gov/pubmed/30300581
http://dx.doi.org/10.1016/j.ccell.2018.08.017

Ejemplares similares